Alpha Tau Medical Ltd
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alpha Tau Medical Ltd. Alpha Tau Medical Ltd. (NASDAQ: DRTS), a clinical-stage oncology therapeutics company headquartered in Jerusalem, Israel, and founded in 2016, develops and seeks to commercialize its proprietary Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid tumors. Alpha DaRT utilizes interstitial radioactive sources, primarily based on radium-224, that release short-lived alpha-emitting atoms to deliver highly potent, localized radiation over several millimeters, enabling conformal treatment of tumors while sparing surrounding healthy tissue; the technology targets localized unresectable, refractory or recurrent tumors previously treated with surgery or conventional radiation, cancers with high unmet needs such as pancreatic adenocarcinoma and glioblastoma, and metastatic tumors in combination with systemic therapies including immunotherapies. The company conducts clinical trials for skin cancer (recurrent cutaneous squamous cell carcinoma), oral cavity cancer, pancreatic cancer, prostate cancer, lung cancer, liver cancer, breast cancer, and glioblastoma multiforme, with preclinical studies for brain and other cancers; operations span Israel, the United States, and global clinical sites in collaboration with leading cancer centers and institutions. Recent developments include the successful treatment of the first patient in its U.S. multi-center pilot study for pancreatic cancer, receipt of a radioactive material license for its New Hampshire commercial-scale manufacturing facility to support Alpha DaRT production starting in 2026, FDA approval of an Investigational Device Exemption for a U.S. pilot study in recurrent glioblastoma multiforme, ongoing patient recruitment in the U.S. pivotal ReSTART trial for skin cancer, and participation in major investor conferences such as the Jefferies Global Healthcare Conference; as of Q3 2025, Alpha Tau reports a cash balance of $75.9 million to fund these advancements toward commercialization.
Company News
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Alpha Tau to Participate in September Investor Conferences
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
New Strong Sell Stocks for July 7th
New Strong Sell Stocks for July 2nd
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Alpha Tau Medical: A Lot Of Shots On Goal
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau to Participate in May Investor Conferences